Attenua Picks Up $35M to Treat Chronic Cough
Mountain View-based biopharmaceuticals startup Attenua, which is developing medicines to treat chronic cough, has raised $35M in a Series A funding. The funding was led by Omega Funds, and also included Abingworth, OrbiMed and Redmile Group. Attenua said that, as part of the funding, Michael Kitt, M.D., the former Chief Medical Officer at Afferent Pharmaceuticals, has been named CEO of the company.
posted on Tuesday, May 1, 2018
Related stories:
> Advanced Cardiac Therapeutics Picks Up $45M
> Chronic Health Capital Makes First Investment
> PneumRx Raises $27M
> Breathe Technologies Takes In $15M
> HeartFlow Picks Up $240M
silicontap.com Home